Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 10, 2009, Pages 1353-1358

  Chunying, Cui ^a   Yunwei, Zhang ^a   Lili, Wang ^a,b   Hu, Liu ^a,b   Guohui, Cui ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

All trans retinoic acid; Anti tumour; Cell cycle; Glutamic acid; Pro drug

Indexed keywords

ALL TRANS RETINOYL GLUTAMIC ACID; ALL TRANS RETINOYL SODIUM GLUTAMATE; LIPOSOME; RETINOIC ACID; RETINOIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; PRODRUG; RETINOYL GLUTAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HL 60; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MELTING POINT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL ROTATION; PARTICLE SIZE; PARTITION COEFFICIENT; SARCOMA; SARCOMA 180; ZETA POTENTIAL; ANIMAL; CELL CYCLE; CHEMISTRY; COMPARATIVE STUDY; SYNTHESIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DNA FRAGMENTATION; GLUTAMATES; HL-60 CELLS; HUMANS; LIPOSOMES; MICE; PRODRUGS; TRETINOIN; TUMOR BURDEN;

EID: 74949129043     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.10.0012     Document Type: Article

References (23)

1. Holland LZ. Developmental biology: a chordate with a difference. Nature 2007; 447: 153-155.
2. Marshall H et al. Retinoids and Hox genes. FASEB J 1996; 10: 969-978.
3. Thaller C, Eichele G. Identification and spatial distribution of retinoids in the developing chick limb bud. Nature 1987; 327: 625-628.
4. Sun SY et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000; 6: 1563-1573.
5. Gulati M et al. Lipophilic drug derivatives in liposomes. Int J Pharmaceutics 1998; 165: 129-168.
6. Komura N et al. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. Leukemia Res 2007; 31: 301-313.
7. Walker JR et al. An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide. Bioorg Med Chem Lett 2002; 12: 2447-2450.
8. Vanhoutte N, Hermans E. Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1. FEBS Lett 2008; 582: 1847-1852.
9. Karunakaran S et al. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J 2008; 414: 343-355.
10. Nawashiro H et al. High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol 2005; 22: 89-91.
11. Kondoh N et al. Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 2007; 31: 81-87.
12. Tsume Y et al. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 2008; 5: 72717-72713.
13. Landowski CP et al. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther 2005; 4: 659-667.
14. DingWet al. The synthesis, distribution, and anti-hepatic cancer activity of YSL. Bioorg Med Chem 2004; 12: 4989-4994.
15. 4 fatty acid-amino acid-derivatives of 1-β- arabinofuranosylcytosine. Eur J Med Chem 2009; 44: 3596-3600.
16. Vaizoglu MO, Speiser PP. The pharmacosome - a novel drug delivery system. Acta Pharm Suec 1986; 23: 163-172.
17. Muindi JR et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52: 2138-2142.
18. Jones DS. Pharmaceutical Statistics. London: Pharmaceutical Press, 2002: 409-424.
19. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 2008; 8: 21-32.
20. Dass CR. Drug delivery in cancer using liposomes. Methods Mol Biol 2008; 437: 177-182.
21. Pitot HC. Hepatocyte death in hepatocarcinogenesis. Hepatology 1998; 28: 1-5.
22. Kerr JF et al. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
23. Gillis JC, Goa KL. Tretinoin A. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Drugs 1995; 50: 897-923.